Lantheus (LNTH)
NASDAQ:LNTH
Top Page
Lantheus
(NASDAQ:LNTH)
Select Model
Select Model
Rating:67Neutral
Price Target:
$82.00
▲(2.46% Upside)
Action:ReiteratedDate:02/26/26
The score is driven primarily by solid multi-year financial strength but a recent TTM slowdown in margins and cash-flow momentum. Technicals are supportive (price above key averages) yet overbought, increasing near-term risk. Valuation is a headwind with a ~31.8 P/E and no dividend yield, while the latest earnings call was neutral with near-term PYLARIFY pressure and 2027-weighted growth catalysts.
Positive Factors
Strong cash generation
Consistent operating and free cash flow in absolute dollars provides durable funding for reinvestment, launches and M&A without immediate financing needs. Even with recent momentum softness, strong cash conversion supports execution of 2027 commercialization plans and shareholder returns over the medium term.
Negative Factors
Core product pricing pressure (PYLARIFY)
Material pricing and competitive headwinds to PYLARIFY threaten the company's largest revenue base, reducing top-line durability and margin leverage. Prolonged price erosion or payer pressures could meaningfully lower cash generation and constrain funding for launches and R&D over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent operating and free cash flow in absolute dollars provides durable funding for reinvestment, launches and M&A without immediate financing needs. Even with recent momentum softness, strong cash conversion supports execution of 2027 commercialization plans and shareholder returns over the medium term.
Read all positive factors
Lantheus (LNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.17B
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)19.2
Beta (1Y)0.53
Revenue Growth1.95%
EPS Growth-60.40%
CountryUS
Employees808
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.67
Shares Outstanding64,605,896
10 Day Avg. Volume744,199
30 Day Avg. Volume1,090,015
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue3.58
Enterprise Value/Gross Profit5.86
Enterprise Value/Ebitda13.69
Forecast
1Y Price Target
$93.33Price Target Upside16.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.19
Revenue Forecast (FY)$1.45B
Lantheus Business Overview & Revenue Model
Company Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultras...
How the Company Makes Money
Lantheus generates revenue primarily through the sale of its diagnostic imaging agents and radiopharmaceuticals. The company's revenue model is based on direct sales to hospitals, imaging centers, and other healthcare providers. Key revenue stream...
Lantheus Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
Balanced / Neutral: The call highlighted meaningful strategic progress — acquisitions (Neuraceq, OCTEVY candidate), a broadened radiodiagnostic pipeline, strong product positions (PYLARIFY volumes, DEFINITY market share), multiple near-term regulatory milestones, and a clear commercialization plan targeting 2027 growth. However, near-term pressures are material: PYLARIFY revenue decline and pricing headwinds, gross margin compression (~289 bps YoY), Q4 cash-flow and free-cash-flow deterioration, and notable one-time integration and litigation costs. Management is taking prudent, deliberate steps (divestiture of SPECT, focusing capital on diagnostics, launch-readiness investments) which support a constructive medium-to-long-term outlook, but the near-term financial headwinds and execution/timing risks balance the positives.Positive Updates
Revenue and Scale
Q4 2025 revenue of $406.8M, up 4% year-over-year; Full-year 2025 revenue of $1,541.6M, up 0.5% YoY. Company impacted ~7 million patients in 2025.
Negative Updates
PYLARIFY Revenue Pressure
PYLARIFY Q4 revenue $240.2M, down 9.7% YoY and flat sequentially; full-year PYLARIFY revenue $989.1M, down 6.5% YoY. Management expects PYLARIFY net revenue to decline 8%–10% YoY in 2026 due to pricing pressure and competitive dynamics.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue and Scale
Q4 2025 revenue of $406.8M, up 4% year-over-year; Full-year 2025 revenue of $1,541.6M, up 0.5% YoY. Company impacted ~7 million patients in 2025.
Read all positive updates
Company Guidance
Lantheus guided 2026 worldwide net revenue of $1.40–$1.45 billion with gross margin near 65.5% and EPS of $5.00–$5.25 (based on ~66 million fully diluted shares), noting an effective tax rate of ~26% and expected net interest/other expense of about $5 million; R&D is planned at ~10–11% of revenue (up ~200 bps), G&A ~10% of revenue, and sales & marketing investment implied around the low‑teens (~12–12.5%) to support upcoming launches. Product and portfolio assumptions include PYLARIFY net revenue down 8%–10% in 2026 (higher volume but modest price erosion and a rolling Q4 transition to a new F‑18 formulation), Neuraceq expected to grow triple‑digits inorganically (Neuraceq contributed $31M in Q4 and $51.4M since acquisition), DEFINITY to grow low‑ to mid‑single digits (DEFINITY >$85M in Q4), and no meaningful commercial contribution from new approvals in 2026 with material impact expected in 2027; management also adjusted the 2025 comparable baseline to $1,424.2M after the SPECT divestiture ($111.4M) and one‑time items, cited a normalized EPS comparison of ~$5.75, and highlighted cash of $359.1M, Q4 operating cash flow of $90.2M and free cash flow of $81.4M, plus $100M of share repurchases in the quarter (leaving $200M authorization).Lantheus Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
74
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.54B | 1.53B | 1.30B | 935.06M | 425.21M |
| Gross Profit | 941.95M | 988.29M | 709.54M | 581.70M | 187.69M |
| EBITDA | 403.64M | 515.27M | 491.00M | 81.83M | -25.00M |
| Net Income | 233.56M | 312.44M | 326.66M | 28.07M | -71.28M |
Balance Sheet | |||||
| Total Assets | 2.23B | 1.98B | 1.65B | 1.32B | 863.78M |
| Cash, Cash Equivalents and Short-Term Investments | 359.12M | 912.81M | 713.66M | 415.65M | 98.51M |
| Total Debt | 738.00K | 619.44M | 616.95M | 583.51M | 191.31M |
| Total Liabilities | 1.14B | 892.33M | 835.26M | 874.11M | 399.35M |
| Stockholders Equity | 1.09B | 1.09B | 815.89M | 447.15M | 464.44M |
Cash Flow | |||||
| Free Cash Flow | 354.05M | 493.13M | 258.70M | 263.43M | 41.78M |
| Operating Cash Flow | 390.14M | 544.75M | 305.26M | 281.78M | 53.92M |
| Investing Cash Flow | -627.17M | -226.01M | 5.94M | -276.55M | 3.68M |
| Financing Cash Flow | -316.58M | -118.54M | -13.06M | 311.69M | -39.33M |
Lantheus Technical Analysis
Positive
80.03
Price Trends
73.57
Positive
68.13
Positive
64.87
Positive
Market Momentum
0.40
Positive
56.30
Neutral
77.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Positive. The current price of 80.03 is above the 20-day moving average (MA) of 77.53, above the 50-day MA of 73.57, and above the 200-day MA of 64.87, indicating a bullish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 56.30 is Neutral, neither overbought nor oversold. The STOCH value of 77.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LNTH.
Lantheus Risk Analysis
Lantheus disclosed 55 risk factors in its most recent earnings report. Lantheus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lantheus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $5.17B | 19.23 | 20.58% | ― | 1.95% | -60.40% | |
67 Neutral | $1.77B | 14.40 | 15.55% | ― | 48.87% | ― | |
55 Neutral | $2.97B | -72.78 | -3.67% | ― | 4.54% | -130.59% | |
54 Neutral | $4.00B | 54.80 | -67.91% | ― | 9.50% | ― | |
53 Neutral | $2.59B | 4.99 | 41.38% | ― | -1.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.49B | -1.35 | -35.16% | 8.48% | -2.55% | 66.00% |
* Healthcare Sector Average
LNTH
Lantheus
80.03
-20.13
-20.10%
PRGO
Perrigo Company
10.83
-13.36
-55.23%
SUPN
Supernus Pharmaceuticals
51.61
19.85
62.50%
ANIP
ANI Pharmaceuticals
79.01
13.00
19.69%
HCM
HUTCHMED
14.98
2.20
17.21%
AMRX
Amneal Pharmaceuticals
12.71
5.28
71.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.